Indication | Oncology |
Status | ‒ ODD granted on December 23th, 2020. ‒ Registration Batch Manufacture planning. |
Product Advantages | Handa is utilizing its ONCORE™ technology to develop improved versions of Oncology drug for reducing the risk associated with sever side effect and improve bioavailability. |
Potential Market | According to the data in 2021 annual report of the brand company, the total sales of the brand drug were approximately US$2 billion. |